Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.

Mathé G, Schally AV, Comaru-Schally AM, Mauvernay RY, Vovan ML, Machover D, Misset JL, Court B, Bouchard P, Duchier J

The Prostate1 Jan 1986Cited by 15 (Europe PMC)

PMID2947053DOI10.1002/pros.2990090404PepBankPUB-02947053

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with prostate carcinoma, triptorelin greatly reduced serum LH.
In plain wordsIn patients with prostate cancer, LH decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum LH
Study
n = 81
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
Treatment with D-Trp-6-LH-RH greatly reduced serum LH and testosterone levels without raising serum prolactin.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705301
02HumanNon-randomized trialEfficacy outcome
In patients with prostate carcinoma, triptorelin greatly reduced serum testosterone.
In plain wordsIn patients with prostate cancer, testosterone decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum testosterone
Study
n = 81
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
Treatment with D-Trp-6-LH-RH greatly reduced serum LH and testosterone levels without raising serum prolactin.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705302
03HumanNon-randomized trialEfficacy outcome
In patients with prostate carcinoma, triptorelin did not raise serum prolactin.
In plain wordsIn patients with prostate cancer, prolactin did not increase during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeSerum prolactin
Study
n = 81
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
Treatment with D-Trp-6-LH-RH greatly reduced serum LH and testosterone levels without raising serum prolactin.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705303
04HumanNon-randomized trialEfficacy outcome
In patients with prostate carcinoma, subjective symptoms improved after 1-2 weeks of triptorelin therapy.
In plain wordsIn patients with prostate cancer, symptoms improved after 1-2 weeks of triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSubjective symptoms
Study
n = 81
Outcome group
Patient-reported outcomes · Cancer
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
After 1-2 weeks of therapy, there was relief of subjective symptoms and a reversal of the signs of prostatism as well as a marked decrease in bone pain.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705304
05HumanNon-randomized trialEfficacy outcome
In patients receiving triptorelin, prostatism improved after 1-2 weeks, with 52 patients symptom-free and 21 mildly affected at 90 days.
In plain wordsIn patients with prostate cancer, prostatism improved during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseProstatism
Study
n = 81
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Patients with complete relief of prostatism
52 patients
at 90 days
Patients with only mild signs and symptoms of prostatism
21 patients
at 90 days
Source sentences
Summary
At 90 days 52 patients had complete relief of prostatism and 21 had only mild signs and symptoms.
3 context sentences(design, population, supporting numbers)
Summary · context
After 1-2 weeks of therapy, there was relief of subjective symptoms and a reversal of the signs of prostatism as well as a marked decrease in bone pain.
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705305
06HumanNon-randomized trialEfficacy outcome
In patients receiving triptorelin, bone pain decreased, with 70 patients pain-free and six reporting mild pain.
In plain wordsIn patients with prostate cancer, bone pain decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone pain
Study
n = 81
Outcome group
Pain · Cancer
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Patients with no bone pain
70 patients
after treatment
Patients with only mild bone pain
6 patients
after treatment
Source sentences
Summary
Seventy patients were experiencing no bone pain and an additional six had only mild pain.
3 context sentences(design, population, supporting numbers)
Summary · context
After 1-2 weeks of therapy, there was relief of subjective symptoms and a reversal of the signs of prostatism as well as a marked decrease in bone pain.
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705306
07HumanNon-randomized trialEfficacy outcome
In patients with prostate carcinoma, triptorelin reverted prostatic size to normal in 26.4% and reduced it by more than 50% in an additional 17.6%, an overall regression rate of 44%.
In plain wordsIn patients with prostate cancer, prostate enlargement regressed completely or partially in 44% during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseProstate enlargement regression
Study
n = 81
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Complete remission of prostatic enlargement
26.4%
prostatic size reverted to normal
Partial remission of prostatic enlargement
17.6%
size reduced by more than 50%
Overall complete plus partial regression
44%
prostatic enlargement
Source sentences
Summary
Prostatic size, evaluated by rectal examination and transabdominal ultrasonography, reverted to normal in 26.4% of patients (complete remission) and was reduced by more than 50% in an additional 17.6% (partial remission), the overall rate of complete plus partial regression of prostatic enlargement being 44%.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705307
08HumanNon-randomized trialEfficacy outcome
In patients receiving triptorelin, prostatic acid phosphatase decreased by more than 50% in 61% of patients.
In plain wordsIn patients with prostate cancer, prostatic acid phosphatase decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseProstatic acid phosphatase
Study
n = 81
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Patients with prostatic acid phosphatase decrease of more than 50%
61%
after treatment
Source sentences
Summary
Prostatic acid phosphatase levels were decreased by more than 50% in 61% of the patients, but this test appears to be a less valid marker than the lipid-associated sialic acid (LASA).
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705309
09HumanNon-randomized trialSafety outcome
In patients with prostate carcinoma, no disease flare occurred during triptorelin treatment.
In plain wordsIn patients with prostate cancer, no disease flare occurred during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeDisease flare
Study
n = 81
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
No flare-up of the disease was encountered, and there were no side effects except for impotence.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705310
10HumanNon-randomized trialSafety outcome
In patients with prostate carcinoma, impotence was the only reported side effect of triptorelin.
In plain wordsIn patients with prostate cancer, impotence was the only reported triptorelin side effect.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableImpotence and other side effects
Study
n = 81
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
No flare-up of the disease was encountered, and there were no side effects except for impotence.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705311
11HumanNon-randomized trialEfficacy outcome
In patients receiving triptorelin, bone lesions improved in 14.8%, rising to 37% after more than 6 months of follow-up.
In plain wordsIn patients with prostate cancer, bone lesions improved during triptorelin treatment and later follow-up.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone lesion improvement
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Cases with major improvement of bone lesions
14.8%
scans, at end of 3-month treatment period
Cases with major improvement of bone lesions
37%
after more than 6 months of follow-up
Source sentences
Summary
Scans showed a major improvement of bone lesions in 14.8% of cases. This response increased to 37% after more than 6 months of follow-up.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Report a problemFND-0294705308
12HumanNon-randomized trialEfficacy outcome
In prostate carcinoma, complete and partial regression with triptorelin did not differ significantly from historical buserelin results.
In plain wordsIn prostate cancer studies, regression rates with triptorelin did not differ significantly from earlier buserelin results.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeRegression versus historical buserelin
Study
n: not reported in source
Comparator
Historical buserelin studies
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
Statistical analyses of results by the method of Lee and Wesley indicated that the incidence of complete and partial regression (CR and PR) observed with D-Trp-6-LH-RH was not significantly different from that recorded in previous studies for another LH-RH analog, Buserelin.
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705312
13HumanNon-randomized trialEfficacy outcome
In prostate carcinoma, complete and partial regression with triptorelin was significantly higher than historical subcapsular orchiectomy results, 44% versus 22%.
In plain wordsIn prostate cancer studies, regression was more frequent with triptorelin than with earlier subcapsular orchiectomy results.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseRegression versus historical orchiectomy
Study
n: not reported in source
Comparator
Historical subcapsular orchiectomy
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Complete plus partial regression, triptorelin
44%
D-Trp-6-LH-RH
Complete plus partial regression, historical subcapsular orchiectomy
22%
subcapsular orchiectomy
Source sentences
Summary
However, CR and PR obtained with D-Trp-6-LH-RH (44%) were significantly higher than with subcapsular orchiectomy (22%).
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-one patients with prostatic carcinoma, eight with stage B, nine with stage C, and 64 with stage D disease, were treated subcutaneously daily for 3 months with the LH-RH agonist D-Trp-6-LH-RH (Decapeptyl) in order to evaluate the incidence of remissions according to WHO recommendations for oncologic trials.
Summary · context
The findings were compared to those obtained with other hormonal therapies of prostatic carcinoma according to the statistical method of "expected response rate" as adapted by Lee and Wesley for phase II trials.
Report a problemFND-0294705313

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.